Prevalence and indicators of fear of melanoma in patients with familial melanoma during surveillance.
C Hinnen, A Boonstra, N Kukutsch...
https://pubmed.ncbi.nlm.nih.gov/32936976Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID06767332
EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
Led by Leiden University Medical Center · Updated on 2025-01-09
30
Participants Needed
2
Research Sites
26 weeks
Total Duration
On this page
Sponsors
L
Leiden University Medical Center
Lead Sponsor
E
Erasmus Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Fear of cancer recurrence (FCR) is a common and distressing issue for patients with familial melanoma, significantly affecting their quality of life. This trial investigates whether Eye Movement Desensitization and Reprocessing (EMDR), a psychological treatment originally used for PTSD and anxiety, can reduce high FCR in these patients. The study compares EMDR to a waiting-list control group in a randomized, non-blinded design. Participants in the intervention group receive an intake session and up to four 90-minute EMDR therapy sessions over approximately four weeks. Those in the waiting-list group wait for six weeks before being offered the same treatment if FCR persists. Assessments occur at baseline, after treatment, and during follow-up periods to measure changes in FCR and quality of life. Throughout the study, participants complete the Cancer Worry Scale (CWS) to evaluate levels of FCR and the EORTC questionnaire to assess quality of life. These evaluations take place before treatment, immediately after, and at two weeks and three months post-treatment. The study aims to track changes in fear and life quality over time, with ongoing monitoring and follow-up as part of the trial process.
CONDITIONS
Brief Title
EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- A score of 16 or higher on the FCRI-NL-SF
- 18 years or older
- Diagnosed with familial melanoma
You will not qualify if you...
- Insufficient knowledge of the Dutch language
- Acute psychiatric disease such as psychosis or suicidal ideation
- Use of variable dose of anxiolytics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 4 weeks
Participants receive an intake session and up to 4 EMDR therapy sessions to reduce fear of cancer recurrence.
1 intake visit and up to 4 treatment visits (in-person)
Follow-up
Duration - 3 months
Participants are assessed for fear of cancer recurrence and quality of life after treatment at 2 weeks and 3 months.
2 follow-up visits (in-person)
Waiting Period
Duration - 6 weeks
Participants assigned to the waiting list wait for 6 weeks before receiving treatment if needed.
No visits during waiting period
Trial Site Locations
Total: 2 locations
1
Leiden University Medical Center
Leiden, South Holland, Netherlands, 2333ZA
Actively Recruiting
2
Leiden University Medical Centre
Leiden, South Holland, Netherlands, 2333ZA
Actively Recruiting
Loading map...
Research Team
S
Sanne K. de Bie, Drs.
C
Chris Hinnen, Dr.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Efficacy of eye movement desensitization and reprocessing therapy for fear of cancer recurrence among cancer survivors: a randomized single-case experimental design.
J Bruin, Y R van Rood, K C M J Peeters...
https://pubmed.ncbi.nlm.nih.gov/37144665The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors.
José A E Custers, Sanne W van den Berg, Hanneke W M van Laarhoven...
https://pubmed.ncbi.nlm.nih.gov/23448956Pediatric seizure-related posttraumatic stress and anxiety symptoms treated with EMDR: a case series.
Elmedina Dautovic, Carlijn de Roos, Yanda van Rood...
https://pubmed.ncbi.nlm.nih.gov/27387846Investigating the effect of Eye Movement Desensitization and Reprocessing (EMDR) on postoperative pain intensity in adolescents undergoing surgery: a randomized controlled trial.
Mohsen Maroufi, Shahla Zamani, Zahra Izadikhah...
https://pubmed.ncbi.nlm.nih.gov/27134066The role of eye movement desensitization and reprocessing (EMDR) therapy in medicine: addressing the psychological and physical symptoms stemming from adverse life experiences.
Francine Shapiro
https://pubmed.ncbi.nlm.nih.gov/24626074Fear of new or recurrent melanoma after treatment for localised melanoma.
Katy J L Bell, Yachna Mehta, Robin M Turner...
https://pubmed.ncbi.nlm.nih.gov/28052599Utilization of health care services in cancer patients with elevated fear of cancer recurrence.
Alexandra Champagne, Hans Ivers, Josée Savard
https://pubmed.ncbi.nlm.nih.gov/29719072Psychosocial Care Needs of Melanoma Survivors: Are They Being Met?
Sabine Fischbeck, Barbara H Imruck, Maria Blettner...
https://pubmed.ncbi.nlm.nih.gov/26296089Surveillance for familial melanoma: recommendations from a national centre of expertise.
A B Halk, T P Potjer, N A Kukutsch...
https://pubmed.ncbi.nlm.nih.gov/30742720